Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg
Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan loxapine succinate
25 mg capsules to Watson Loxitane 25 mg capsules following a single, oral 25 mg (1 x 25 mg)
dose administration under fasting conditions.